Study S001922

Effect of Tirzepatide-Induced Weight Loss on Adipose Tissue in Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06893211
Acronym: TABFAT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: SINGLE
Status: COMPLETED
Enrollment: 34
Start: 2025-03-18
Primary completion: 2025-11-29
Lead sponsor: University Medical Centre Ljubljana
Conditions: Obesity
Interventions: DRUG:Tirzepatide; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: YES

Registered primary outcomes

Change in Brown Adipose Tissue Activity and Volume [Baseline to Week 24]
Change in Molecular Markers of Browning in Subcutaneous White Adipose Tissue [Baseline to Week 24]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016495	Effect of tirzepatide-induced weight loss on adipose tissue in obesity: rationale and design of the randomized placebo-controlled Tirzepatide Brown and Beige Adipose Tissue Activation (TABFAT) trial. Herman R, Trials	2025	Protocol	PMID 40847412 DOI	cites ClinicalTrials.gov:NCT06893211; registry reference DERIVED:40847412